Fund moves
16.3%Stake · was 16.3%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SCTX · NASDAQ · Biological Products, (No Diagnostic Substances) · No 10-K yet
Scribe Therapeutics (SCTX) · oqro.io/stocks/SCTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$12.07−1.15 (−8.70%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Scribe Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Scribe Therapeutics (SCTX) was filed with the SEC in the last 90 days.
No trade in Scribe Therapeutics (SCTX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−44.2% (−$9.58) from Jul 24, 2026 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $21.65 on Jul 24, 2026 to $12.07 on Nov 20, 2026 (−44.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Alameda, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$229M
Short interest: 1.67M shares sold short (8.8% of shares outstanding), +49.5% vs the previous count, 4.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
Among this manager's largest new positions for Q3 2026. From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Jul 24, 2026, SCTX is down 44.2% and the index fund is down 6.6%: 38 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SCTX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Revenue
$1.64M
−91.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$11.3M
This quarter −$11.3M, a year earlier −$11.6M
Net debt
—
Debt —, cash $172M, at Sep 30, 2026
Net income, last 12 months
—
Operating loss: profit did not cover interest (last 2 quarters)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
0 certified in FY2026 Q3, vs 2 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Fails to deliver: 58K shares (about $1.19M) were not delivered on time for settlement on Oct 16, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 47.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (19.7% on ATS, 27.7% with other brokers), close to its 12-week average of 46.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (18.9%), INTELLIGENT CROSS LLC (11.5%), SIGMA X2 (9.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Records